Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Maguire

Showing results (71-80 of 159) with videos related to

Pageof 16
Sort By:
Clinical Pediatrics|June 5, 2010
Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitisRobert Baker, V Marc Tsou, John Tung, et al.
European Journal of Clinical Nutrition|February 28, 2025
Moderate-to-vigorous and light-intensity aerobic exercise yield similar effects on food reward, appetitive responses, and energy intake in physically inactive adultsShu-Shih Hsieh, Angelos Bala, Kapris Layzell, et al.
Nano Letters|December 15, 2016
Tuning Nonlinear Mechanical Mode Coupling in GaAs Nanowires Using Cross-Section Morphology ControlA P Foster, J K Maguire, J P Bradley, et al.
Clinical Pharmacokinetics|July 12, 2011
Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux diseaseBrinda K Tammara, Janice E Sullivan, Kim G Adcock, et al.
Digestive Diseases and Sciences|July 8, 2010
Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux diseaseJaroslaw Kierkus, Wanda Furmaga-Jablonska, Janice E Sullivan, et al.
Blood Advances|December 4, 2018
Application of a public health strategy to large-scale point-of-care screening for sickle cell disease in rural sub-Saharan AfricaC Chunda-Liyoka, A A Kumar, P Sambo, et al.
Journal of Clinical Pharmacology|September 21, 2010
A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux diseaseRobert M Ward, Gregory L Kearns, Brinda Tammara, et al.
Nature|May 30, 2014
mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert)Joseph T Rodgers, Katherine Y King, Jamie O Brett, et al.
Gut|December 17, 2017
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)Silvio Danese, Séverine Vermeire, Paul Hellstern, et al.
Science (New York, N.Y.)|August 28, 2012
PTF 11kx: a type Ia supernova with a symbiotic nova progenitorB Dilday, D A Howell, S B Cenko, et al.
Pageof 16

Showing results (71-80 of 159) with videos related to

Sort By:
Pageof 16
Clinical Pediatrics|June 5, 2010
Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitisRobert Baker, V Marc Tsou, John Tung, et al.
European Journal of Clinical Nutrition|February 28, 2025
Moderate-to-vigorous and light-intensity aerobic exercise yield similar effects on food reward, appetitive responses, and energy intake in physically inactive adultsShu-Shih Hsieh, Angelos Bala, Kapris Layzell, et al.
Nano Letters|December 15, 2016
Tuning Nonlinear Mechanical Mode Coupling in GaAs Nanowires Using Cross-Section Morphology ControlA P Foster, J K Maguire, J P Bradley, et al.
Clinical Pharmacokinetics|July 12, 2011
Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux diseaseBrinda K Tammara, Janice E Sullivan, Kim G Adcock, et al.
Digestive Diseases and Sciences|July 8, 2010
Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux diseaseJaroslaw Kierkus, Wanda Furmaga-Jablonska, Janice E Sullivan, et al.
Blood Advances|December 4, 2018
Application of a public health strategy to large-scale point-of-care screening for sickle cell disease in rural sub-Saharan AfricaC Chunda-Liyoka, A A Kumar, P Sambo, et al.
Journal of Clinical Pharmacology|September 21, 2010
A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux diseaseRobert M Ward, Gregory L Kearns, Brinda Tammara, et al.
Nature|May 30, 2014
mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert)Joseph T Rodgers, Katherine Y King, Jamie O Brett, et al.
Gut|December 17, 2017
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)Silvio Danese, Séverine Vermeire, Paul Hellstern, et al.
Science (New York, N.Y.)|August 28, 2012
PTF 11kx: a type Ia supernova with a symbiotic nova progenitorB Dilday, D A Howell, S B Cenko, et al.
Pageof 16